Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular diabetes and weight-loss treatments in new markets.
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting a profit of $22.86 per share, according to data compiled by LSEG.
Eli Lilly stock jumped 3% in premarket trading.